0001104659-26-028971
SEC filingBicycle Therapeutics plc (BCYC) reported collaboration revenue of $72.6 million for FY 2025, a 106% YoY increase from $35.3 million in 2024, driven by accelerated recognition from Novartis and Bayer collaborations following termination notices. Despite revenue growth, the company posted a net loss of $219.0 million, widening 30% YoY from $169.0 million, due to surging R&D expenses at $240.3 million (up 39% YoY) from zelenectide pevedotin trials and discovery efforts. G&A rose 10% to $79.4 million. Loss from operations deepened to $247.1 million. Balance sheet strengthened with $628.1 million in cash equivalents, supporting operations into 2026 amid workforce reductions targeting 50% expense cuts. Operating cash burn hit $249.7 million, reflecting clinical investments. Strategic reprioritization focuses on nuzefatide pevedotin and BRC pipeline, deprioritizing zelenectide pevedotin. No product revenue yet; profitability hinges on clinical progress and partnerships. Cash position funds runway past 12 months, but ongoing losses signal need for funding.
Bicycle Therapeutics reported FY 2025 collaboration revenue of $72.6M, surging 106% YoY from $35.3M, fueled by $38.8M from Novartis (full recognition post-termination notice) and $5.5M from Bayer. Net loss expanded to $219.0M (30% YoY worse vs. $169.0M), driven by R&D at $240.3M (+39% YoY) from zelenectide pevedotin Phase II/III and new trials, plus discovery. G&A hit $79.4M (+10%). Operating loss $247.1M. Cash burn intensified with $249.7M operating outflow. Balance sheet: $628.1M cash, $717.6M assets, $610.0M equity. Strategic shifts include reprioritizing to nuzefatide pevedotin/BRC, 30% workforce cut targeting 50% expense reduction.
Solely collaboration revenue: $72.6M vs. $35.3M prior. Novartis contributed bulk via termination acceleration; Bayer from program end. Ionis declined post-research completion. No product sales; future tied to milestones/royalties from Ionis/Bayer. Terminations (Genentech Aug 2025, Novartis Feb 2026) signal near-term revenue drop, but pipeline focus on internal oncology assets.
No gross profit (pre-revenue biotech). Operating margin N/A; loss from ops -340% of revenue vs. deeper prior loss. R&D dominated at 75% of opex ($240.3M/$319.7M), up from prior due to trials. G&A 25%. Losses persist sans commercialization; cost cuts aim mitigation.
Ops cash use $249.7M (vs. $164.7M prior), from clinical ramps. Investing $2.4M capex. Financing outflow $0.1M post-debt payoff. Net cash decrease $251.4M; ending $628.1M cash (total cash/restricted $339.2M? Reconciliation notes). Debt extinguished Jul 2024. Equity $610.0M; runway >12 months. Leases $20.8M committed.
Expenses to fall ~50% post-reprioritization/workforce cuts ($8.0M severance). Focus: nuzefatide pevedotin Phase II pancreatic, BT1702 IND-enabling. Risks: trial delays, funding needs amid losses. Cash funds ops 12+ months; partnerships eyed for BT7480.